

2 May 2023

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Suspension of Trading Pending 2022 Annual Report

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, provides the following update in relation to the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2022 (the "2022 Annual Report").

In accordance with the listing rules, the Company was required to publish its audited 2022 Annual Report by 30 April 2023; however, due to the late appointment of BDO LLP as the Company's new auditors in January 2023, BDO LLP have requested additional time in order to complete their audit work. While the audit process has yet to be concluded, the Directors have been advised by the auditors that the audit is substantially complete and accordingly, the Company is targeting the publication of the 2022 Annual Report as soon as the auditor completes their work, which is expected to be completed shortly.

As a result of the delay in publishing the 2022 Annual Report, the Company's shares will be temporarily suspended from the Official List and from trading on the London Stock Exchange with effect from 7.30am today. Following the publication of the 2022 Annual Report the Company will make application for the suspension to be lifted.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION EU NO. 596/2014, AS RETAINED AND APPLICABLE IN THE UK PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

-ENDS-

Enquiries:

Roquefort Therapeutics plc Stephen West (Chairman) / Ajan Reginald (CEO)	+44 (0)20 3290 9339
Hybridan LLP (Joint Broker) Claire Louise Noyce	+44 (0)203 764 2341
Optiva Securities Limited (Joint Broker) Christian Dennis	+44 (0)20 3411 1881
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale	+44 (0)20 7466 5000

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines.

Roquefort Therapeutics' portfolio consists of five early, novel, never patent-protected pre-clinical anti-cancer medicines.

The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SUSUPURCAUPWUQP